Cyclosporine A in Combination With Abacavir Sulfate, Lamivudine, and Zidovudine and Lopinavir/Ritonavir in HIV
Status:
Completed
Trial end date:
2008-01-01
Target enrollment:
Participant gender:
Summary
Cyclosporine A (CsA) is a common long-term treatment used to inhibit the immune response in
transplant patients who receive donor organs. CsA may also help people with HIV. The purpose
of this study is to determine the safety of and immune response to CsA when given with
abacavir sulfate (ABC), lamivudine (3TC), and zidovudine (AZT), (ABC/3TC/AZT) and
lopinavir/ritonavir (LPV/r) to HIV infected adults in the early stages of infection.
Study hypothesis: The combination of CsA and LPV/r given to acutely infected individuals will
result in lower levels of proviral DNA and latent infectious virus at 48 weeks compared to
acute infected individuals treated with LPV/r alone.
Phase:
Phase 2
Details
Lead Sponsor:
National Institute of Allergy and Infectious Diseases (NIAID)